Autoimmune Hemolytic Anemia Treatment Guidelines

Introduction to AIHA Treatment

The American Society of Hematology recommends corticosteroids as first-line treatment for AIHA, with specific regimens based on AIHA subtype, followed by rituximab or splenectomy for refractory cases 1

The initial dose of prednisone or prednisolone should be 1 mg/kg/day PO for 4-6 weeks, as recommended by the European Hematology Association, with a slow taper over 6-12 months after response 1
Corticosteroids are effective in 70-85% of patients, according to the National Institutes of Health 1

Clinical improvement is expected within 2 weeks, and patients should be monitored for hemoglobin, reticulocytes, LDH, and bilirubin levels, as suggested by the American College of Physicians 1

Rituximab is increasingly preferred as second-line treatment, with a standard dose of 375 mg/m² weekly for 4 weeks, as recommended by the European Society for Medical Oncology 1
Splenectomy is effective in approximately 70% of cases, with a cure rate of up to 20%, according to the Society of Surgical Oncology 1

Patients should be kept warm and avoid cold exposure, as recommended by the American Red Cross 1
Immunosuppressive drugs, such as azathioprine, cyclophosphamide, and cyclosporine, may be used in addition to corticosteroids, as suggested by the National Kidney Foundation 1

For patients with severe hemolysis and life-threatening anemia, high-dose intravenous methylprednisolone and blood transfusion may be necessary, as recommended by the American College of Emergency Physicians 1
Corticosteroids are first-line treatment, and azathioprine should be avoided if possible, according to the European League Against Rheumatism 1
IVIG is relatively safe during pregnancy, as suggested by the American College of Obstetricians and Gynecologists 1

5% of AIHA cases remain DAT-negative, and specialized testing for IgA autoantibodies, warm IgM, or low-affinity IgG should be considered, as recommended by the International Society for Laboratory Hematology 1
Tapering corticosteroids too quickly leads to relapse, and inadequate duration of treatment (minimum 6 months recommended) can result in complications, according to the American Society of Hematology 1

Don't withhold transfusion in life-threatening anemia despite compatibility issues, and least incompatible units may be necessary, as recommended by the American Association of Blood Banks 1
Always investigate for underlying conditions (lymphoproliferative disorders, autoimmune diseases, infections) in cases of secondary AIHA, and treating the underlying condition may improve AIHA, according to the World Health Organization 1